Sustained HBsAg Clearance in HBeAg-Negative Patients Treated with Peg-IFNα-2b

203 patients with baseline HBsAg <200 IU/mL, HBeAg negativity, and undetectable HBV DNA were analyzed for sustained HBsAg clearance after Peg-IFNα-2b therapy. The median follow-up duration was 96 weeks, with 44 patients experiencing HBsAg reversion. Chaojing Wen authored this retrospective study, which was last updated on 2026-05-20.

Use Cases

• Predicting long-term treatment success based on end-of-treatment HBsAb levels mentioned in the description.
• Analyzing risk factors for HBsAg reversion based on consolidation therapy duration.
• Modeling the optimal follow-up time point for patients achieving HBsAg clearance.
• Studying the relationship between HBV DNA detection and HBsAg reversion in patients with low baseline antigen.

Strengths

• 203 patient records provide a substantive cohort for analysis.
• Median follow-up duration of 96 weeks offers longitudinal data.
• Specific clinical thresholds are defined, such as baseline HBsAg <200 IU/mL and EOT HBsAb >1000 IU/mL predicting 100% sustained clearance.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The 25.2 KB file size suggests a very limited scope, likely containing summary statistics rather than patient-level data.

Provenance

Source

figshare

Collection Method

Retrospective study analyzing patient records.

Time Range

The median follow-up duration was 96 weeks (range:72 to 120 weeks).

Freshness

Last updated 2026-05-20 10:43:29; freshness should be verified.